These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31050628)

  • 1. The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
    Huang DB; Charrier C; Le Bras C; Hawser S; Noviello S
    J Med Microbiol; 2019 Jun; 68(6):898-902. PubMed ID: 31050628
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Noviello S; Magnet S; Hawser S; Huang DB
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
    Lodise TP; Bosso J; Kelly C; Williams PJ; Lane JR; Huang DB
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
    Krievins D; Brandt R; Hawser S; Hadvary P; Islam K
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2834-40. PubMed ID: 19414572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Bryant AE; Gomi S; Katahira E; Huang DB; Stevens DL
    J Med Microbiol; 2019 Mar; 68(3):456-466. PubMed ID: 30676310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of human plasma on the antimicrobial activity of iclaprim in vitro.
    Laue H; Valensise T; Seguin A; Hawser S; Lociuro S; Islam K
    J Antimicrob Chemother; 2007 Dec; 60(6):1388-90. PubMed ID: 17951265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
    Huang DB; Magnet S; De Angelis S; Holland TL; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):154-158. PubMed ID: 30266399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
    Noviello S; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Scaramucci A; Torres A; Huang DB
    J Med Microbiol; 2020 Apr; 69(4):625-630. PubMed ID: 32195649
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.
    Entenza JM; Haldimann A; Giddey M; Lociuro S; Hawser S; Moreillon P
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3635-41. PubMed ID: 19564362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
    Farrell DJ; Turner LL; Castanheira M; Jones RN
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
    Bhavnani SM; Hammel JP; Van Wart SA; Rubino CM; Reynolds DK; Forrest A; Drusano GL; Khariton T; Friedland HD; Riccobene TA; Ambrose PG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):372-80. PubMed ID: 25367904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2009 May; 53(5):2171-5. PubMed ID: 19289528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.
    Smart JI; Corey GR; Stryjewski ME; Wang W; Barriere SL
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):268-271. PubMed ID: 28038840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro bactericidal activity of iclaprim in human plasma.
    Laue H; Valensise T; Seguin A; Lociuro S; Islam K; Hawser S
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4542-4. PubMed ID: 19651909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
    Zhang H; Xiao M; Kong F; O'Sullivan MV; Mao LL; Zhao HR; Zhao Y; Wang H; Xu YC
    Int J Antimicrob Agents; 2015 Apr; 45(4):347-50. PubMed ID: 25649348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.